Vivante GMP Solutions has completed process optimisation activities related to the upcoming production of a GMP clinical plot of an Oxford University adenovirus-based malaria vaccine.

The Jenner Institute at Oxford University is involved in multiple vaccine projects for various infectious diseases. These programs are funded in part by the European Malaria Vaccine Initiative and the Grand Challenges in Global Health initiative.

The Grand Challenges in Global Health is jointly funded by Bill Gates and his wife fund, The Bill and Melinda Gates Foundation, the Wellcome Trust, and the Canadian Institute of Health Research.

President and CEO at Vivante, David Enloe said: “We are very pleased to be working with Oxford on this important project. Oxford has multiple vaccine initiatives which represent the next generation of addressing many serious public health threats. The work Vivante has done thus far to optimise this product’s GMP production process is something our team is very proud of.”

Adrian Hill, director of the Jenner Institute and chairman of the Centre for Clinical Vaccinology and Tropical Medicine at Oxford University, said: “Vivante has been important to the Jenner Institute in our development of new approaches to vaccinating against malaria. I look forward to a growing relationship with Vivante as these programs progress through clinical trials.

No related posts.

When Big Pharma invents a new drug, it works like a cash machine for these Giant Pharma. With USA patents protecting new discoveries from competition, drug developers Giant like Pfizer, GlaxoSmithKline, and AstraZeneca can charge whatever they want for their little miracles.

Until, that is E day, the patent expiry date. Then it’s goodbye profits, and hello generics! Behind every new drug is a generic copycat. In India, it works in different ways. Any pharma company can produce any drugs that domestic market need. Live is the first.

This year 2009, according to Standard & Poor’s research, branded drug sales are set to decline for the first time. That’s partly due to the economy, but also due to increasing competition from generics. IMS Health, the industry’s clearinghouse for drug sales data, says that $24 billion worth of branded drugs this year will get generic competitors, up from $18 billion last year. The figure will hit $30 billion by 2012.

Launched: January 2005
2008 sales: $900 million
Branded equivalent: Duragesic, by Janssen, 2008 sales of $1.1 billion

Launched: July 2007
2008 sales: $779 million
Branded equivalent: Norvasc, by Pfizer (PFE, Fortune 500), 2008 sales of $2.2 billion

Launched: May 2008
2008 sales: $675 million
Branded equivalent: Toprol, by AstraZeneca (AZN), 2008 sales $807 million

Launched: February 2005
2008 sales: $671 million
Branded equivalent: Lamictal, by GlaxoSmithKline (GSK), 2008 sales $1.6 billion

Launched: September 2008
2008 sales: $610 million
Branded equivalent: Risperdal, by Janssen, 2008 sales $2.1 billion

Launched: July 2008
2008 sales: $609.8 million
Branded equivalent: Prilosec, by AstraZeneca, 2008 sales $1.1 billion

Launched: November 2005
2008 sales: $599 million
Branded equivalent: Zithromax, by Pfizer, 2008 sales $429 million

Launched: December 2006
2008 sales: $521 million
Branded equivalent: Wellbutrin, by Biovail (BVF), 2008 sales $579 million

Where there are generic drugs, there are lawyers. Biovail tried to avoid the coming generic onslaught for its antidepressant Wellbutrin by launching an extended-release version of the drug, called Wellbutrin XL, in August 2003.

Remmember that buying generic drugs is to save you money.

Related posts:

1. World Top Ten Antimicrobial Agents and generic drugs list

The US Food and Drug Administration has approved four vaccines for the H1N1 influenza virus, while other companies, including GlaxoSmithKline, have reported promising results from clinical studies with a single-dose vaccine.

Related posts:

1. Malaria Vaccine it’s not a dream

The IMI budget for 2008–2017 is €2 billion ($2.9 billion), with half coming from the European Community and half from industry. In April 2008, IMI received 134 proposals, 15 of which were selected to receive €246 million (approximately $359 million). The funding available for the second proposal call is €156.3 million ($227.9 million), with €76.8 million ($112 million) to be provided by the European Commission and €79.5 million ($116 million) to be provided by EFPIA member companies.

No related posts.

The global pharmaceutical markets expanded to $770 billion in 2008. Biotechnology took $120 billion (15,6%) and generic drugs once again increased it share of the global pie to $80 billion (10,4%). The antibacterial market leaders were Zosyn, Floxin and Cravit.
Several blockbuster drugs got patent expiry. Lipitor retained its top position as the best selling global drug with $12.4 B in sales, Plavix won the second place with sales of $5.6 billion and the third place belonged to Enbrel (Etanercept) – $3.4 billion.

The global antimicrobial therapeutic market was $24 billion in 2008 with 14 products recording sales of more than $1 billion. Truveda, Valtrex and Atripla were the leading antiviral agents. Valtrex contributed $1.7 Billion in total sales $43.0 B of GSK.

As of September 06, 2009, there are 4186 generic drugs and dosages on the list: link 1 (PDF). You can find one and get the generic version at lower price elsewhere.

You may find Generic version of Lipitor, Floxin, Valtrex  at several pharmacies, one of them is www.IndianPharmacy.org an indian online pharmacy supplies more than 400 generic medicines.

Related posts:

1. Generic drugs superstars

Are you going to die if you do not have your regular dinner at a Italy restaurant? May be no. Your secretary will call Pizza Inn and your life is saved.

Are you going to die if you do not find out any one to give a kidney for free when yours is need to be replace? Yes, you will be, if you can not afford a to buy one .

How many HIV patent are going to die because they can not afford the drugs?

Fact 1: 30 to 36 million pe0ple living with AIDS (2007) [1].

Fact 2: Over three million people living with HIV/AIDS in the developing world receive antiretroviral therapy (ART). However, the medicines and diagnostic tools available are inadequate to respond fully to their needs. In addition, seven million people are in need of treatment and are still waiting for access. [2]

Fact 3: According to UNAIDS and WHO, an estimated 250,000 to 350,000 deaths were averted in 2005 because of
expanded access to AIDS treatment.

Fact 3: combination of three treatments (Stavudine, Lamivudine and Nevirapine) costs around $20.000 per patient per year (PPY) if you buy brand-name. But most of poor HIV patient can prolong their lives with Triomune (Cipla production), the Indian generic version is available in the developing world for just $800, more than 30 times cheaper than the official versions of these drugs. Dr Yusuf Hamied is a hero. He helps people while his business is growing fast.

I have no conclusion right here but sure you have got one in you mind.

Talk it lough out to save lives. And don’t be ignorant when buying high price brand name drug while you can ask the doctor, pharmacist for the lower price substitution. It’s GENERIC DRUG.

Related posts:

1. WANTED: Criminal AIDS Drug Pricing

The back of the postcard explains: “Richard T. Clark, CEO of Merck & Co. Pharmaceuticals, is wanted for pricing Merck’s HIV/AIDS drug Isentress so high that it is now the most expensive first-line HIV/AIDS drug. Recently approved by the FDA as a first-line treatment, Isentress is up to three times more expensive than other first-line treatments—as much as $12,864 per patient per year. This criminal pricing threatens to limit the ability of Medicaid and AIDS Drug Assistance programs nationwide to provide crucial lifesaving drugs to it patients.”

“It is criminal for Merck to have priced its newest HIV/AIDS drug, Isentress at an astronomical $12,864 per patient per year – especially now that the FDA has approved the drug for first-line use, vastly increasing the drug`s market,” said Michael Weinstein, AIDS Healthcare Foundation President. “AHF has repeatedly requested that Merck lower the price of Isentress so that more patients will be able to access it. Merck has refused to do so. Cash-strapped ADAP and Medicaid programs will go bankrupt if these government programs-and the taxpayers who fund them-are forced to continue subsidizing the cost of new medicines like Isentress that are priced unjustifiably high.”

Related posts:

1. Dont want to die, buy it

Prescription drugs can be a costly medical expense for every one, especially for older people and those who are chronically ill (diabetes, hypertension, pain, cancer etc), since you have to take drugs on daily basic.

However, each country has a law that lets your pharmacists/pharmacies substitute less expensive generic drugs for many brand-name drugs. Depending on your prescription needs, your savings cost could be significant. Before talking with your doctor or pharmacist about switching to low cost generic drugs, there are things you need to know about generic drugs benefit and the law.

No related posts.

Related posts:

1. World Top Ten Antimicrobial Agents and generic drugs list